Viral Hepatitis C

Research and Markets - Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Hepatitis C virus affects between 130–150 million individuals every year globally of which approximately 700,000 people die. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.

It was estimated that there could be rise from $18700 million to $22721.1 million in hepatitis drug market by the end of forecasting period reflecting a sluggish CAGR of 3.3%.

    Related Conference of Viral Hepatitis C

    October 29-30, 2018

    4th World Congress on Digestive & Metabolic Diseases

    | San Francisco, California, USA
    November 07-08, 2018

    World Summit on Liver Cirrhosis and Hepatitis

    December 17-18, 2018

    3rd World Liver Congress

    Abu Dhabi, UAE
    January 30-31, 2019

    16th World Congress on Gastroenterology & Therapeutics

    Bangkok, Thailand
    March 04-05, 2019

    20th World Congress on Gastroenterology

    Berlin, Germany
    June 17-18, 2019

    World Liver Conference 2019

    Columbus, Ohio, U.S.A
    July 08-09, 2019

    14th Euro-Global Gastroenterology Conference

    Zurich, Switzerland
    July 15-16, 2019

    7th International Conference on Hepatology

    Sydney, Australia
    October 14-15, 2019

    19th World Gastroenterologists Summit

    Sydney, Australia

    Viral Hepatitis C Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in